Mobile clinic study of extended-release buprenorphine for opioid use disorder
Treatments studied
Part of Mental health clinical trials.
This trial tests a long-acting, once-monthly injection of buprenorphine (BRIXADI) given from a mobile pharmacy clinic. It aims to see if this approach is acceptable and practical for people with opioid use disorder, making treatment more accessible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give consent in English or Spanish.
- You have or have had moderate-to-severe opioid use disorder (OUD) diagnosed by a doctor.
- You plan to stay in the area for the duration of the study.
- You are not pregnant and do not have serious medical conditions or suicidal thoughts.
- You are not allergic to latex, as the medication needle cap contains natural rubber latex.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a once-monthly injection of buprenorphine (called extended-release buprenorphine, or XR-B) works well for people in prison who are already in a medication program for opioid use disorder. It looks at preferences and outcomes in the last months before release.
This trial tests different doses of buprenorphine to find the safest and most effective one for treating opioid use disorder and preventing overdose. It is for people who have used fentanyl and are starting or continuing buprenorphine treatment.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This study tests whether switching from daily buprenorphine/naloxone (Suboxone) to a long-acting injectable buprenorphine (XRB) is safe and effective for men who are unsentenced and in jail for at least 4 days. It aims to see if the injection can help continue treatment without needing daily medication.
This trial compares taking buprenorphine by mouth versus as an injection for opioid use disorder. It aims to see which option helps people stay on treatment and reduces opioid use over about a year.
This study tests whether extra support in community settings (like mobile units or outreach) helps people who are starting buprenorphine for opioid use disorder stay on treatment. It focuses on helping you continue your medication and stay healthy.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.